Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
- Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit
- The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types
- Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patients
- The transaction valued at up to $1.5 billion including $1.1 billion cash upfront
Paris, London, 06 July 2026 — Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners’ seventh exit in three years.
